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Abstract
Background Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic
tool in those with cancer. A range of pre-defined thresholds currently exist within the literature to define low skeletal
muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle
index (SMI) and density (SMD) within the literature, across a range of common solid tumours.
Methods A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in
patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer,
whether curative or non-curative disease, the anthropomorphic parameter studied, threshold used to define low SMI
and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded.
Results Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The me-
dian prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was
little variation in the prevalence of low SMI and SMD when studies were divided into curative and non-curative cohorts
—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided
into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI
(46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%,
56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI
(Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%).
Conclusions Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre-existing
dogma of the determinants of prevalence.
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Introduction
One in two people born in the UK after 1960 will be
diagnosed with cancer during their lifetime.1 In an age of
precision medicine, factors that aid prediction of clinical out-
comes in patients with cancer are vital in determining the
modality and extent of treatment. Body composition analysis
using computed tomography (CT) has garnered considerable
interest with regards to its utility in predicting likely outcome.
Within the last decade, there has been a substantial volume
of research exploring the relationship between skeletal
muscle volume2 and density,3 and outcomes in patients with
operable and advanced cancers across a breadth of histolog-
ical subtypes and treatment modalities. The expansion in the
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number of studies of CT-based body composition analysis and
outcomes is attributable to the importance of body composi-
tion, the routine use of CT in the staging of tumours, and
advances in computer software to carry out such analysis.4
In particular, skeletal muscle mass and density have been
shown to be consistently associated with poor outcome in pa-
tients with cancer.2,3 Skeletal muscle mass is most often calcu-
lated from the cumulative volume of the intra-abdominal
musculature on a CT image slice, generally at the level of
the third lumbar vertebra, normalized by the square of the pa-
tient’s height in metres (skeletal muscle index, SMI), analo-
gous to that of BMI. A range of pre-defined thresholds have
been proposed in studies from various populations,5–8 al-
though, at present, there are no universal thresholds in use.
The skeletal muscle density (SMD) can also be derived
from the CT image slice. However, the basis of the SMD mea-
surement is less clear than that of SMI because unlike SMI,
SMD is a measurement unique to the CT image.9 In theory,
striated skeletal muscle, free from fat infiltration, should have
a greater density on CT analysis compared against that with
fat deposition.10,11 Within the literature, low SMD is defined
by a mean muscle attenuation below an established thresh-
old, usually at the level of the third lumbar vertebra, and
measured in Hounsfield units (HU). Similar to that of the as-
sessment of the SMI, pre-determined thresholds have been
established from studies conducted across a range of popula-
tions; however, again, no universally used thresholds exist for
the defining of low SMD.6,8,12
A lack of universally used thresholds for the determination
of low SMI and SMD is just one of the limitations of CT anal-
ysis of body composition parameters for prognostication.
With a variety of thresholds in use, interpretation of the ex-
ternal validity of results and comparison becomes difficult.
Nevertheless, recent studies have demonstrated excellent
inter-observer and intra-observer agreement across a range
of software packages in both those with13 and without
cancer.14 Therefore, despite the limitations associated with
CT-derived SMI and SMD measurements, they provide a
routine clinically available objective measure and offer the
potential for unique insight into the relationship between
the tumour and host. The aim of the present systematic
review was to assess the prevalence of low SMI and SMD,
taking into account currently established thresholds for these
CT-derived analysis and tumour stage in a range of common
solid tumours.
Patients and methods
The protocol for this systematic review was developed using
PRISMA guidelines.15 A systematic search of PubMed was car-
ried out to identify studies reporting CT analysis of SMI and
SMD in patients with cancer. The search was carried out using
the following MESH terms: ‘body composition’, ‘computed to-
mography (CT)’, ‘cancer’, ‘skeletal muscle’, ‘skeletal muscle in-
dex’, ‘skeletal muscle density’, ‘sarcopenia’, ‘myosteatosis’,
and ‘cachexia’. The search was conducted from the start of
the relevant database to the 30th of August 2020. Reference
lists from studies of relevance were then hand-searched for
any other eligible studies. All relevant studies assessing the
relationship between CT analysis of skeletal muscle mass
and density, with outcomes in the chosen cancer groups,
were included. Conference abstracts, non-English language
studies, as well as meta-analyses and systematic reviews
were excluded. Studies were then individually screened for
relevance based on title alone, prior to review of abstracts,
and later, full texts (J. M.). The type of cancer, whether cura-
tive or non-curative, the anthropomorphic parameter stud-
ied, threshold used to define low SMI and SMD, and the
prevalence of these anthropomorphic measurements within
the population were recorded. Studies included in the cura-
tive cohort were those with patients who had TNM Stages
I–III disease treated with curative intent. Studies involving
patients with unresectable disease, TNM Stage IV disease or
those that examined at metastases were included in the
non-curative cohort. Any issues relating to the
interpretation of significance or discrepancies in validity of
results within the individual studies, were addressed by
re-examination with a senior colleague (R. D. D.) and discus-
sion with the senior author (D. C. M.). The STROBE checklist,
a validated methodological quality assessment tool, was then
used to assess all eligible studies for quality.16
Results
A total of 1225 studies were identified on initial search of the
PubMed database. Following the exclusion of duplicates by
the screening of titles, 1163 abstracts were reviewed. There
were 321 full papers deemed suitable for review, with 160
meeting inclusion criteria for qualitative analysis (Figure 1).
A total of 161 records identified did not meet the eligibility
criteria and were therefore excluded. Studies were excluded
from qualitative analysis for the following reasons: their be-
ing systematic reviews and meta-analyses, using total psoas
area for calculation of SMI, using CT analysis of vertebral level
other than L3 for calculation of total muscle area, those that
did not report an SMI (cm2/m2) or SMD (HU), as well as
studies that did not publish thresholds used in determination
of low SMI and SMD.
Qualitative analysis
There were 42 063 patients were included in the 160 studies
selected for qualitative analysis. Of these studies, 156
(n = 37 527 patients) reported an assessment of SMI alone
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using a defined threshold, four studies (n = 4536 patients) re-
ported SMD alone using a defined threshold and 31 studies
reported both SMI and SMD using defined thresholds
(n = 10 363 patients). Prevalences of low SMI and SMD are re-
ported as median (interquartile range).
Skeletal muscle index
Of the 156 studies assessing SMI in cancer patients (refer to
Table S1), 55.8% (n = 87) involved patients with curative dis-
ease and 44.2% (n = 69) involved patients with non-curative
disease. Twenty-five per cent (n = 39) used thresholds de-
scribed by Martin,6 30.1% (n = 47) used those described by
Prado,7 and 44.9% (n = 70) reported low SMI using different
thresholds (refer to Table 1). In studies not using thresholds
defined by Martin or Prado (refer to Table S3), values for
low SMI ranged from ≤25.6617 to ≤55.4 cm2/m218–20 for male
patients and ≤21.7317 to ≤46.4 cm2/m221 for female patients.
One study by Aleixo et al. reported the proportion of patients
low SMI across multiple thresholds.22 An SMI below the de-
fined threshold was reported in 40.2% (n = 15, 103 patients).
Across the entire cohort, the median proportion of patients
with low SMI was 43% (30.1–57.1). In those studies of patients
with curative cancer, the median low SMI was 40.7%
Figure 1 Flow diagram of literature search and included/excluded studies.
Table 1 The number of studies and the thresholds used to define low
SMI in patients with cancer
Cancer subtype Martin Prado Other Total (n)
Colorectal 15 13 11 39
Oesophageal 3 12 11 26
Gastric 7 4 10 21
Hepatobiliary 2 4 20 26
Pancreatic 6 7 10 23
Breast 3 5 4 12
Lung 2 2 5 9
Total (n) 38 47 71 156
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(27.5–51.3) compared with 48.4% (30.9–60.1) in studies of pa-
tients with non-curative disease. With regard to the preva-
lence of low SMI across the entire cohort, using specific
thresholds, median values were similar in studies using
thresholds described by either Martin or Prado, 48.9%
(37.1–59.3) and 49.9% (39.4–60.2), respectively. However,
low SMI was less prevalent in studies using other thresholds
at 36.0% (21.3–50.1; refer to Table 2). This was likely repre-
sentative of these studies using threshold values lower than
that of both Martin and Prado; meaning less patients would
be classified as having low SMI.
Skeletal muscle density
Skeletal muscle density was assessed using defined thresholds
in a total of 35 studies (refer to Table 3). Of the 35 studies
reporting SMD, 37% (n = 13) used contrast enhanced CT imag-
ing, while just 6% (n = 2) reported that non-contrast scans
were used. The remaining 57% (n = 20) of studies did not dis-
close whether contrast enhanced scans were used to deter-
mined SMD (refer to Table S2). A low SMD was identified in
48.6% (n = 5038) of patients, from the 31 studies assessing
both SMI and SMD. In the four studies analysing SMD alone,
29.0% (n = 1316) of patients were reported as having an
SMD below the threshold used. 48.5% (n = 16) of studies
assessing SMD used threshold values described by Martin
et al.6 to stratify patients into those with low and high SMD.
In the remaining 17 studies assessing SMD, threshold values
used ranged from ≤22.0 HU23 to ≤44.4 HU24–26 in male pa-
tients and ≤23.523 to ≤39.324 in female patients. Similar to
their analysis of SMI, Aleixo et al. reported the proportion of
patients with low SMD across multiple thresholds.23 Across
the whole cohort, the prevalence of low SMD was 49.4%
(31.7–58.5). The median percentage of patients with low
SMD was higher in those in the non-curative cohort than in
the curative cohort: 55.3% (38.5–64.7) and 37.8%
(32.2–52.2), respectively. When comparing studies using the
thresholds for low SMD defined by Martin et al. with studies
using other thresholds, the prevalence of low SMD was simi-
lar, at 52.4% (37.5–58.8) and 48.6% (33.3–53.5), respectively
(refer to Table 4).
Cancer specific analysis
Colorectal
The largest volume of studies assessing skeletal muscle
volume and density involved those with colorectal cancer
(n = 39 studies). There were13 589 patients included in these
39 studies; 23 of which were constituted by those with cura-
tive disease, with 16 involving patients with non-curative
disease. Thresholds described by either Martin or Prado were
used to define low SMI in 15 (nine curative and six non-cura-
tive) and 13 (six curative and seven non-curative) studies, re-
spectively. The remaining 11 studies used other thresholds to
classify patients into low and high SMI cohorts (refer to Table
1). Threshold values for SMI ranged from ≤32.527 to ≤54.028
in male patients and ≤28.627 to ≤42.129 in female patients.
Across the whole cohort of patients with colorectal cancer,
the prevalence of low SMI was 46.0% (32.3–59.8). When
assessing the curative cohort, the median percentage of
patients with low SMI was 41.1% (29.1–55.1) compared
with 49.1% (42.6–60.8) in the non-curative cohort (refer to
Table 5). With reference to patients with low SMI across
Table 2 The percentage prevalence of low skeletal muscle index by threshold used
Overall Martin Prado Other
All 43.0% (30.1–57.1) 48.9% (33.1–58.7) 49.9% (39.4–60.2) 36.0% (21.3–50.1)
Curative 40.7% (27.5–51.3) 42.9% (30.6–49.9) 56.7% (43.7–65.3) 32.9% (24.6–41.5)
Non-curative 48.4% (30.9–60.1) 54.1% (46.2–60.6) 47.7% (39.4–60.1) 47.9% (21.3–63.3)
Table 3 The number of studies and the thresholds used to define low
skeletal muscle density in patients with cancer
Cancer subtype Martin (n) Other (n) Total (n)
Colorectal 7 5 12
Oesophageal 2 1 3
Gastric 1 1 2
Hepatobiliary 0 4 4
Pancreatic 3 4 7
Breast 3 2 5
Lung 1 1 2
Total (n) 17 18 35
Table 4 The percentage prevalence of low skeletal muscle density by threshold used
Overall Martin Other
All 49.4% (31.7–58.5) 52.4% (37.5–58.8) 48.6% (33.3–53.5)
Curative 37.8% (32.2–52.2) 40.7% (27.5–51.3) 42.9% (30.6–49.9)
Non-curative 55.3% (38.5–64.7) 48.4% (30.9–60.1) 54.1% (46.2–60.6)
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specific thresholds, the prevalence in both curative and
non-curative studies was 50.4% (44.0–59.8) in those using
Martin’s parameters, 47.7% (39.4–60.2) in those using
Prado’s thresholds, and 27.5% (24.7–42.3) in studies using
other thresholds. This would suggest that patients with
colorectal cancer were more likely to be considered to have
low skeletal muscle volume in studies using the thresholds
described by Martin. When comparing curative and
non-curative studies, the prevalence of low SMI was 49.8%
(31.5–59.8) compared with 54.1% (47.9–58.9) in studies using
Martin’s thresholds, 53.8% (42.8–60.1) compared to 43.7%
(39.2–58.5) in studies using Prado’s threshold, and 26.6%
(24.8–34.5) compared with 46.8% (33.1–55.4) in studies using
other thresholds. When assessing curative and non-curative
cohorts, one might expect those with curative disease to
have higher skeletal muscle volume, as reflected by studies
using the thresholds described by Martin. However, the in-
verse of this was demonstrated in studies using thresholds
described by Prado, where low SMI was more prevalent in
the curative cohort (refer to Table 6).
A total of 12 studies composed of 7154 patients with
colorectal cancer assessed SMD using CT (refer to Table 3).
Of these studies, 75% (n = 8) were composed of those with
curative disease and 25% (n = 4) had non-curative disease.
Seven studies (four curative and three non-curative) used
the thresholds described by Martin to define low SMD. In
the remaining five studies that examined SMD in those with
colorectal cancer, four included patients with curative disease
and one study included those with non-curative disease. The
thresholds used to define low SMD ranged from ≤22.023 to
≤38.230 HU in male patients and ≤23.523 to ≤33.6 HU30 in fe-
male patients. Across the whole cohort of patients with colo-
rectal cancer, the median percentage of those with a low
SMD was 52.1% (29.6–64.1). When assessing the curative co-
hort, the median percentage of patients with low SMD was
52.1% (31.2–53.5) compared with 44.5% (23.4–65.9) in the
non-curative cohort (refer to Table 7). When examining spe-
cific thresholds, the median percentage of patients with low
SMD using thresholds defined by Martin et al. was 52.1%
(35.0–67.5), and 29.6% (27.4–52.5) in the cohort using other
thresholds (refer to Table 7).
Oesophageal
Twenty-six studies, comprised of 4205 patients, reported CT
analysis of SMI and SMD in patients with oesophageal cancer
(refer to Table 1). All 26 studies reported the proportion of
patients with low SMI determined by defined indices, with
three studies also assessing SMD. One study included
male-only patients in their cohort for analysis.31 Of the stud-
ies, 69.2% (n = 18) included patients with curative disease
with the remaining 30.8% (n = 8) comprising of patients with
non-curative cancer. Twelve studies (46.2%) assessed SMI
using thresholds described by Prado et al.,7 with only 11.5%
(n = 3) using thresholds described by Martin et al.6 The re-
maining 42.3% (n = 11) of studies used other thresholds to
define low SMI. Thresholds used to define low SMI ranged
Table 5 The percentage prevalence of low skeletal muscle index by cancer type
Cancer subtype Overall cohort Curative Non-curative
Colorectal 46.0% (32.3–59.8) 41.1% (29.1–55.1) 49.1% (42.6–60.8)
Oesophageal 49.8% (39.6–61.5) 47.9% (34.3–60.7) 52.9% (47.4–62.0)
Gastric 35.7% (22.9–42.9) 29.2% (15.8–36.1) 47.9% (36.9–63.8)
Hepatobiliary 41.1% (30.6–58.7) 46.5% (40.5–57.8) 34.8% (15–59)
Pancreatic 32.3% (22.1–48.6) 32.5% (24.5–47.4) 63.4% (57.2–64.9)
Breast 34.0% (16.4–42.2) 25.6% (13.6–35) 49.0% (36.4–60.2)
Lung 49.5% (42.2–60.9) 42.2% (37.8–55.5) 50.3% (47.6–58.4)
Table 6 The percentage prevalence of low skeletal muscle index by threshold used in those with colorectal cancer
Overall Martin Prado Other
All 46.0% (32.3–59.8) 50.4% (44.0–59.8) 47.7% (39.4–60.2) 27.5% (24.7–42.3)
Curative 41.1% (29.1–55.1) 49.8% (31.5–59.8) 53.8% (42.8–60.1) 26.6% (24.8–34.5)
Non-curative 49.1% (42.6–60.8) 54.1% (47.9–58.9) 43.7% (39.2–58.5) 46.8% (19.4–63.9)
Table 7 The percentage prevalence of low skeletal muscle density by threshold used in those with colorectal cancer
Overall Martin Other
All 52.1% (29.6–64.1) 52.1% (35.0–67.5) 29.6% (27.4–52.5)
Curative 52.1% (31.2–53.5) 45.4% (36.9–60.9) 41.1% (29.1–52.8)
Non-curative 44.5% (23.4–65.9) 64.2% (41.8–67.5) 24.7%a
aCohort with a solitary study.
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from ≤43.132 to ≤5533–36 in male patients and ≤32.732 to
≤41.137 in female patients. Across the entire cohort, the
prevalence of low SMI was 49.8% (39.6–61.5). With regard
to curative and non-curative cohorts, prevalence of low SMI
was similar with 47.9% (34.3–60.7) and 52.9% (47.4–62.0), re-
spectively (refer to Table 5). Similar median percentages of
those with low SMI were also observed when comparing
studies using Prado’s thresholds to the studies using other
threshold values: 49.4% (34.4–57.4) and 50.1% (35.7–70.4),
respectively (refer to Table 2).
Of the studies, 11.5% (n = 3) identified also analysed SMD
using defined thresholds.32,38,39 Two of these studies used
thresholds described by Martin to define low SMD: one with
curative cancer patients and the other non-curative. The re-
maining study used an alternative threshold to Martin (male
patients ≤35.9, female patients ≤24.8) to determine low
SMD in non-curative oesophageal cancer patients (refer to
Table 3).
Gastric
Twenty-one studies, which assessed low SMI using defined
thresholds across a total of 4774 patients with curative and
non-curative gastric cancer, were included in the qualitative
analysis (refer to Table 1). Two of these studies also assessed
low SMD using defined thresholds26,40 (refer to Table 3).
There were 66.7% (n = 14) of studies of patients with curative
disease, with 33.3% (n = 7) analysing those with non-curative
cancer. Seven studies (33.3%) used thresholds described by
Martin et al. to define low SMI, and 19% (n = 4) used those de-
scribed by Prado. The remaining 47.6% (n = 10) studies used
alternative thresholds. Threshold values ranged from
≤32.527 to ≤49.041 in male patients and ≤28.627 to
≤34.926,42–44 in female patients. Across the entire cohort,
the prevalence of low SMI was 35.7% (22.9–42.9) in those
with gastric cancer. A higher median percentage was present
in studies of non-curative disease, 47.9% (36.9–63.8), com-
pared to those of curative disease, at 29.2% (15.8–36.1) (refer
to Table 5). A similar variation in the prevalence of low SMI
was also observed when individual thresholds were analysed.
In studies using thresholds described byMartin and Prado, the
median percentage of patients with low SMI was 41.8% (33.2–
50.3) and 39.8% (36–43.5), respectively. Studies using other
thresholds were noted have a lower prevalence of low SMI,
with a median percentage of 21.1% (13.2–29.4) (refer to Table
2).
Two studies (9.5%) reported low SMD using defined
indices. One study assessed SMD in a non-curative cohort
using thresholds described by Martin et al. The other
study used alternative thresholds to assess low SMD (refer
to Table 3).
Hepatobiliary
There were 5265 patients included in the 26 studies assessing
skeletal muscle volume using CT in those with hepatobiliary
malignancies (refer to Table 1). Of these 26 studies, 15.4%
(n = 4) also assessed SMD. 34.6% (n = 9) studies included pa-
tients with curative disease, with 65.4% (n = 15) comprising
of those with non-curative cancer. One study included a co-
hort of male-only patients undergoing treatment for
non-curative hepatobiliary cancer.45 Most studies, 76.9%
(n = 20), used thresholds other than those described by either
Martin or Prado to define low SMI. Thresholds used ranged
from ≤3646 to ≤55.419 in male patients and ≤29.621 to
≤46.425 in female patients. Only 15.4% (n = 4) of studies used
thresholds described by Prado to define low SMI, and just
7.7% (n = 2) used those described by Martin et al. (refer to
Table 2). Across the entire cohort, the prevalence of low
SMI was 41.1% (30.6–58.7). Surprisingly, the median percent-
age of those with low SMI was less in the non-curative cohort
than in the curative disease cohort: 34.8% (15.0–59.0) com-
pared with 46.5% (40.5–57.8) (refer to Table 5). This is likely
related to the majority of studies in the non-curative cohort
using different thresholds to those described by either Martin
or Prado and is supported by the median percentage of those
with low SMI in the alternative-threshold cohort being simi-
lar, at 37.6% (26.6–60.1) (refer to Table 1).
Four studies that comprised of 1632 patients assessed
SMD in those with hepatobiliary cancers (refer to Table 3).
Three studies included those with non-curative disease and
the remaining study included patients with curative cancer.
All four studies used thresholds other than those described
by Martin et al. The prevalence of low SMD across the entire
cohort was 56.8% (48.6–70.0) (refer to Table 8).
Table 8 The percentage prevalence of low skeletal muscle density by cancer type
Cancer subtype Overall cohort Curative Non-curative
Colorectal 52.1% (29.6–64.1) 52.1% (31.2–53.5) 44.5% (23.4–65.9)
Oesophageal 54.3% (52.1–56.4) 58.5%a 50.0%a
Gastric 71.2% (64.9–77.6) 83.9%a 58.5%a
Hepatobiliary 56.8% (48.6–70.0) 48.8%a 65.0% (56.8–75.0)
Pancreatic 55.3% (24.7–64.2) 44.5% (23.4–65.9) 55.3%
Breast 52.6% (36.8–59.6) 36.8% (35.4–44.7) 72.8% (66.2–79.4)
Lung 19.3% (14.7–23.8) NR 19.3% (14.7–23.8)
aCohort with a solitary study.
No studies reported skeletal muscle density in patients with curative lung cancer.
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Pancreatic
A total of 4689 patients were included in the 23 studies that
used CT imaging to analyse SMI in those with curative and
non-curative pancreatic cancer (refer to Table 8). Of the 23
studies included in the qualitative analysis, 26.1% (n = 6) also
assessed SMD using defined thresholds.47–50 A further study
analysing SMD in isolation, using a defined threshold, was
also included.51 Of the studies assessing SMI, 30.4% (n = 7)
used the thresholds described by Prado, with 26.1% (n = 6)
using those described by Martin et al. The remaining 43.5%
(n = 10) of studies used thresholds of different values.
Thresholds used in these studies ranged from ≤36.252 to
≤55.420 in male patients and from ≤29.652 to ≤38.918,20 in
female patients. Across the entire cohort, the prevalence of
low SMI was 32.3% (22.1–48.6). A higher prevalence of low
SMI was presented in the non-curative cohort, at 63.4%
(57.2–64.9), in comparison with only 32.5% (24.5–47.4) in
the curative patient cohort. A range in the prevalence of
low SMI was also noted when analysing cohorts of studies
using specific thresholds (refer to Table 5). Studies using
thresholds described by Prado et al. had a median percent-
age of patients with low SMI of 63.4% (57.2–64.9). This was
the highest of all specific thresholds, with studies using
Martin et al.’s parameters having a median percentage of
49.8% (31.3–57.9), and those in the other threshold cohort
have a median percentage of 32.3% (22.1–48.6). This can
be attributed to the majority of studies using Prado’s thresh-
olds being comprised of patients with non-curative disease,
hence the similar median percentages. This was also the case
in studies using thresholds other than those described by
either Prado or Martin mainly involving those patients with
curative disease (refer to Table 2).
Seven studies involving 1539 patients assessed SMD in
those with pancreatic cancer using CT imaging (refer to Table
3). Of the studies, 85.7% (n = 6) involved those with curative
disease. Three studies used thresholds described by Martin
et al.6 to define low SMD, with the remaining four studies
using different thresholds. Across the entire cohort, the prev-
alence of low SMD was 55.3% (24.7–64.2) (refer to Table 8).
Breast
Twelve studies comprising of 4889 female patients with
breast cancer were identified and included in the qualitative
analysis (refer to Table 1). Of the studies, 66.7% (n = 8) in-
cluded those with curative disease, with the remaining four
studies including those with non-curative disease. 41.7%
(n = 5) of studies used thresholds described by Prado et al.
to assess low SMI and 25% (n = 3) used those described by
Martin et al. The remaining 33.3% (n = 4) used thresholds
of <40 cm2/m2. Across the entire cohort, the prevalence of
low SMI was 34% (16.4–42.2). A lower median percentage
was noted in those with curative disease, with 25.6%
(13.6–35.0) having low SMI, compared with non-curative
disease, with a median percentage of 49% (36.4–60.2) pa-
tients having low SMI (refer to Table 5).
Five studies were identified, comprising of 4036 patients in
total, that assess SMD in those patients with breast cancer
(refer to Table 3). Three of the studies assessed those with
curative disease and the other two studies examined those
with non-curative breast cancer. Thresholds for low SMD
described by Martin et al. were used in three studies. The re-
maining two studies used ≤37.8 HU as the threshold to define
those with low SMD. Across the entire cohort, the prevalence
of low SMD was 52.6% (36.8–59.6) (refer to Table 8).
Lung
Nine studies were identified which met the inclusion criteria;
involving 1586 patients, they used CT imaging to assess
skeletal muscle in those with lung cancer (refer to Table 1).
Three studies included individuals with curative disease, with
six including patients with non-curative or palliative lung can-
cer. One study included a cohort of male-only patients.53 Two
studies used the thresholds described by either Martin or
Prado to define low SMI respectively. The remaining five
studies used thresholds ranging from ≤25.6325 to ≤5554 in
male patients, and from ≤21.7317 to ≤41.155 in female pa-
tients. Across the entire cohort, the median percentage of
those with low SMI was 49.5% (42.2–60.9) (refer to Table 5).
Two studies assessed SMD in those with lung cancer.
Both studies involved those with non-curative disease
(refer to Table 3). One study used thresholds described by
Martin et al. to define low SMD.56 The other study used a
threshold of ≤28 HU in male patients and ≤23.8 in female
patients.53
Discussion
The present systematic review included 160 studies, including
more than 42 000 patients, that used CT imaging to deter-
mine SMI and SMD in patients with cancer. In this substantial
cohort it was of interest that both a low SMI and a low SMD
had a percentage prevalence between 35% and 50% and that
this was similar irrespective of threshold used, tumour type,
and stage of disease. Therefore, it would appear that poor
muscle quantity and quality are endemic in patients with can-
cer and that such poor muscle status occurs at diagnosis.
There is now a substantial literature that shows the
detrimental impact that low SMI and SMD have on survival
outcomes of patients with cancer.2,3 However, in the present
review, low skeletal muscle mass (and density) had similar
prevalence across cancer types. Given that there is wide var-
iation in survival across cancer types this would suggest that
body composition is not the main determinant of survival. It
may be that the prognostic value of SMI reflects its measure
of the nutritional and functional reserve of the cancer patient
and that this reserve is eroded by the magnitude of the
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immune/inflammatory challenge posed by the tumour to the
host. Indeed, previous studies have shown that systemic in-
flammatory response is associated with a more aggressive tu-
mour type and57 low SMI and SMD on CT analysis58 and
survival.59,60 It is therefore imperative that body composition
be used in conjunction with other factors, such as systemic
inflammation, to stage the host, as well as staging of the
tumour.61
Patients with cancer often experience anorexia, loss of
weight and skeletal muscle mass as the cancer progresses,
and systemic inflammation.62 This is termed cancer cachexia
and has been shown to be associated with poorer outcomes.
Despite the impact cancer cachexia has on outcomes for pa-
tient with cancer, the pathogenesis for the changes in body
habitus is not clearly understood.63 Patients with certain can-
cers, such as lung and gastrointestinal, are often thought of
as having higher losses of weight and skeletal muscle mass.
However, the results of this systematic review clearly show
that low SMI and SMD are endemic across all cancer types,
present in both curative and non-curative cohorts (refer to
Tables 5 and 8). This is made evident in comparison of prev-
alence of low SMI in curative colorectal cancer studies using
Prado’s thresholds, 53.8% (42.7–60.1), with those in studies
of patients with curative oesophageal cancer 47.2% (30.1–
60.1) or non-curative pancreatic cancer 63.9% (59.8–65.1)
using the same thresholds. The results of this systemic review
challenge the perceived phenotype hypothesized for individ-
uals with specific cancers. This in turn suggests that body
composition may only be one of number of factors determin-
ing the outcome of those with cancer.
There are several limitations of this systematic review. First,
the studies included were mainly retrospective with implica-
tions for the introduction of sample bias. However, the effect
of this is likely to be minimized due to the volume of studies
included. Second, heterogeneity existed across the included
studies with a range of threshold values used to define low
SMI and SMD. Specifically, nearly half of all studies reporting
assessment of SMI included used a threshold other than those
described by Martin or Prado et al. Similarly, nearly half of the
studies assessing SMD used thresholds other than those de-
scribed by Martin et al., limiting comparison and subsequent
comment on overall prevalence of muscle status. However,
when comparing just these threshold values, the median over-
all prevalence of low SMI was 49% and 50%, respectively. Fur-
thermore, when these studies were stratified by curative and
non-curative disease, there was little variation in the preva-
lence of low SMI (43% vs. 57%) and (54% vs. 48%), respectively
(shown in Table 2). Nevertheless, universal thresholds will be
required to reliably determine the prevalence of low SMI
and SMD in patients with cancer and allow for future investi-
gation of the effect of body composition parameters on out-
comes. Third, although the majority of studies assessing SMI
reported the vertebral level analysed, calculation used and
the normalization, over half of the included studies (57%)
assessing SMD failed to report important technical consider-
ations such as which phase of CT scan the image used to deter-
mine the mean muscle attenuation was taken. This has the
potential to introduce further confounding variables into the
methodology and supports the argument for standardized
protocols. Finally, age-related sarcopenia (age at cancer diag-
nosis) is a potential confounding variable in the present analy-
sis. Since Martin et al. provided thresholds for both SMI and
SMD, age was compared in the Martin studies (n = 38), across
the curative (n = 21), and non-curative cohorts (n = 17). This
analysis showed that the mean age was similar in the curative
and non-curative cohorts (64 ± 8 and 62 ± 5 years, respec-
tively) and therefore unlikely to be a major confounding factor
in the present analysis. Nevertheless, it will be important to
carry out analysis in multiple tumour types and stages of dis-
ease using the same methodology to eliminate the above po-
tentially important confounding factors and to confirm the
present observations.
In conclusion, low SMI and SMD are endemic across a
range of cancer types and disease stage. To date, there has
been a belief that skeletal muscle parameters differ between
cancers which are curable vs. more advanced stages. The
findings herein challenge this belief with levels of prevalence
observed. Further multicentre studies are required to pro-
duce international disease-specific thresholds for clinically
relevant CT analysis of body composition.
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